Interius BioTherapeutics, a preclinical stage gene therapy company, has announced a manufacturing partnership with WuXi Advanced Therapies (WuXi ATU) to bring its innovative INT-2104 gene delivery product to the market.
By leveraging WuXi ATU’s Contract Testing, Development and Manufacturing Organization (CTDMO) platform, Interius aims to manufacture INT-2104 – an off the shelf lentivector product designed to create autologous chimeric antigen receptor (CAR) T cells directly in vivo in a patient’s body – in accordance with Good Manufacturing Process (GMP) standards for a Phase I clinical trial. This cutting-edge gene therapy could revolutionise the treatment of B cell malignancies.
Interius is proud to partner with WuXi ATU, a leading provider of integrated plasmid and vector manufacturing services, to provide an innovative process for the manufacture of Phase I clinical material.
Our process, which leverages existing industry standard manufacturing processes, is easily scalable to meet the demands of late-stage trials and commercial scale applications. We are confident that our process will help streamline the transition into cGMP settings for the manufacture of Phase I clinical material.
Interius has taken a giant leap towards fulfilling its mission of extending CAR T therapies to patients everywhere, with the successful scaling of their proprietary process to 200L by WuXi ATU. According to Dr. Phil Johnson, Chief Executive Officer of Interius, this breakthrough is integral to the development of their lentivirus vector platform, which is widely used in the production of cell therapy products for both autologous and allogeneic ex vivo CAR cell therapies.
About Interius BioTherapeutics
Interius BioTherapeutics is transforming the field of gene therapy with its breakthrough platform for in vivo cell-specific gene delivery. Founded on inventions from the renowned laboratory of Dr. Saar Gill, a physician-scientist at the Center for Cellular Immunotherapies at the University of Pennsylvania, Interius BioTherapeutics is pioneering a multi-product potential in the preclinical stage. With headquarters in Philadelphia, PA, Interius BioTherapeutics is revolutionizing the world of gene therapy.